BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23656974)

  • 1. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
    Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
    Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble AXL is ubiquitously present in malignant serous effusions.
    Flem Karlsen K; McFadden E; Flørenes VA; Davidson B
    Gynecol Oncol; 2019 Feb; 152(2):408-415. PubMed ID: 30448261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
    Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
    Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B; Baekelandt M; Shih IeM
    Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
    Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
    Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezrin Is Associated with Disease Progression in Ovarian Carcinoma.
    Horwitz V; Davidson B; Stern D; Tropé CG; Tavor Re'em T; Reich R
    PLoS One; 2016; 11(9):e0162502. PubMed ID: 27622508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
    Vaksman O; Davidson B; Tropé C; Reich R
    Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.
    Brusegard K; Stavnes HT; Nymoen DA; Flatmark K; Trope CG; Davidson B
    Virchows Arch; 2012 Feb; 460(2):193-202. PubMed ID: 22249560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
    Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
    Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic role of BAP1 in serous effusions.
    Davidson B; Tötsch M; Wohlschlaeger J; Hager T; Pinamonti M
    Hum Pathol; 2018 Sep; 79():122-126. PubMed ID: 29802871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.
    Bock AJ; Nymoen DA; Brenne K; Kærn J; Davidson B
    Hum Pathol; 2012 May; 43(5):669-74. PubMed ID: 21855113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
    Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
    Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
    Dos Santos MV; Holth A; Bischof K; Davidson B
    Clin Exp Metastasis; 2024 Feb; 41(1):69-76. PubMed ID: 38141113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
    Davidson B
    Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions.
    Sivertsen S; Berner A; Michael CW; Bedrossian C; Davidson B
    Acta Cytol; 2006; 50(6):603-7. PubMed ID: 17152269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
    Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
    Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival.
    Davidson B; Rosenfeld YB; Holth A; Hellesylt E; Tropé CG; Reich R; Yisraeli JK
    Hum Pathol; 2014 Jul; 45(7):1520-8. PubMed ID: 24814803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
    Davidson B; Stavnes HT; Hellesylt E; Hager T; Zeppa P; Pinamonti M; Wohlschlaeger J
    Hum Pathol; 2016 Jan; 47(1):104-8. PubMed ID: 26520416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.
    Davidson B; Risberg B; Goldberg I; Nesland JM; Berner A; Tropé CG; Kristensen GB; Bryne M; Reich R
    Am J Surg Pathol; 2001 Dec; 25(12):1493-500. PubMed ID: 11717538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.